PTC Therapeutics (PTCT) revenue breakdown
By product, Collaboration and license revenue is the largest at 55% of fiscal 2025 revenue; Royalty revenue grew fastest, 120% a year over 5 years.
By region, United States is the largest at 51% of fiscal 2024 revenue, growing 36% a year over 7 years.
Revenue by product
Fiscal years, as PTC Therapeutics reports them in its 10-K filings; fiscal 2025 total $1.8B.
| Products | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration and license revenue | $1M | $20M | $2M | $16M | $43M | $55M | $50M | $100M | $304,000 | $998M | 55% |
| Net product revenue | $81M | $174M | $263M | $291M | $333M | $429M | $535M | $638M | $582M | $587M | 32% |
| Royalty revenue | — | — | — | — | $5M | $55M | $114M | $169M | $204M | $244M | 13% |
| Manufacturing revenue | — | — | — | — | — | — | — | $8M | $2M | — | — |
| Translarna | — | — | — | — | — | — | — | $23M | $19M | -$99M | -5% |
Revenue by region
Fiscal years, as PTC Therapeutics reports them in its 10-K filings; fiscal 2024 total $807M.
| Regions | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Share |
|---|---|---|---|---|---|---|---|---|---|
| United States | $49M | $94M | $117M | $186M | $297M | $382M | $532M | $413M | 51% |
| Non-US | $145M | $171M | $190M | $194M | $242M | $317M | $406M | $394M | 49% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for PTCT.
Open PTCT in InvestinglyQuestions
Where does PTC Therapeutics make its money?
In fiscal 2025, by product: Collaboration and license revenue $998M, Net product revenue $587M, Royalty revenue $244M, Translarna -$99M.
From PTC Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.